{
    "data": [
        {
            "id": 2562730,
            "title": "BioHarvest Sciences Partners with Saffron Tech to Innovate Saffron Production",
            "description": "<p></p><p>An announcement from BioHarvest Sciences ( <a data-ticker=\"BHST\" href=\"https://www.tipranks.com/stocks/bhst\">(BHST)</a> ) is now available.</p>\n<p></p>\n<p></p><p>BioHarvest Sciences has announced a strategic partnership with Saffron Tech to develop and commercialize saffron-derived botanical compounds using BioHarvest’s Botanical Synthesis platform. This collaboration aims to revolutionize saffron production by making it more consistent, scalable, and sustainable, addressing the high costs and supply chain challenges traditionally associated with saffron cultivation. The partnership is expected to accelerate the path to market for saffron’s health-promoting compounds, with BioHarvest planning to manufacture and market these compounds as nutraceutical products.</p>\n<p>The most recent analyst rating on <a data-ticker=\"BHST\" href=\"https://www.tipranks.com/stocks/bhst\">(BHST)</a> stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/bhst/forecast\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Stock Forecast page</a></span>.</p>\n<p><b><u>Spark’s Take on BHST Stock</u></b></p>\n<p>According to Spark, TipRanks’ <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/artificial-intelligence\">AI</a> Analyst, BHST is a Neutral.</p>\n<p>BioHarvest Sciences faces significant financial challenges, with high leverage and negative equity impacting its long-term sustainability. While technical indicators show some positive momentum, the valuation remains unattractive due to ongoing losses. The earnings call provided a positive outlook with strong revenue growth and strategic initiatives, but increased expenses and net losses remain concerns.</p>\n<p>To see Spark’s full report on BHST stock, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/bhst/ai-stock-analysis\" target=\"_blank\" ;=\"\" rel=\"nofollow\">click here</a></span>. </p>\n<p><b><u>More about BioHarvest Sciences</u></b></p>\n<p>BioHarvest Sciences Inc. is a biotechnology company that specializes in its patented Botanical Synthesis technology platform. The company focuses on producing plant-based molecules in a consistent, scalable, and cost-effective manner without the need for traditional cultivation. Their market focus includes nutraceutical products leveraging the functional benefits of botanicals.</p>\n<p><b>Average Trading Volume:</b> 59,480</p>\n<p><b>Technical Sentiment Signal:</b> Buy</p>\n<p><b>Current Market Cap:</b> $192.7M</p>\n<p></p>\n<p></p><p>See more insights into BHST stock on <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/bhst\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Consumer-Defensive-6-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/bioharvest-sciences-partners-with-saffron-tech-to-innovate-saffron-production",
            "author": "TipRanks Canadian Auto-Generated Newsdesk",
            "pub_date": "2025-10-30 20:45:54",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2562686,
            "title": "China Pacific Insurance Releases Q3 Solvency Report",
            "description": "<p></p><p>The latest announcement is out from China Pacific Insurance (Group) Co ( <a data-ticker=\"HK:2601\" href=\"https://www.tipranks.com/stocks/hk:2601\">(HK:2601)</a> ).</p>\n<p></p>\n<p></p><p>China Pacific Insurance (Group) Co., Ltd. has released an overseas regulatory announcement in compliance with the Hong Kong Stock Exchange’s listing rules. The announcement, signed by Chairman Fu Fan, includes a summary of the third quarter solvency report for Pacific Health Insurance Co., Ltd., indicating the company’s ongoing regulatory transparency and commitment to maintaining solvency standards.</p>\n<p>The most recent analyst rating on <a data-ticker=\"HK:2601\" href=\"https://www.tipranks.com/stocks/hk:2601\">(HK:2601)</a> stock is a Hold with a HK$35.00 price target. To see the full list of analyst forecasts on China Pacific Insurance (Group) Co stock, see the HK:2601 <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/hk:2601/forecast\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Stock Forecast page</a></span>.</p>\n<p><b><u>More about China Pacific Insurance (Group) Co</u></b></p>\n<p>China Pacific Insurance (Group) Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the insurance industry. The company primarily offers a range of insurance products and services, focusing on both life and non-life insurance sectors, and is listed on the Hong Kong Stock Exchange.</p>\n<p><b>Average Trading Volume:</b> 20,624,864</p>\n<p><b>Technical Sentiment Signal:</b> Buy</p>\n<p><b>Current Market Cap:</b> HK$371B</p>\n<p></p>\n<p></p><p>Find detailed analytics on 2601 stock on <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/hk:2601\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1150180799-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/china-pacific-insurance-releases-q3-solvency-report-4",
            "author": "TipRanks HongKong Auto-Generated Newsdesk",
            "pub_date": "2025-10-30 20:40:16",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2562642,
            "title": "Silicom Reports Q3 2025 Results with Strategic Wins and Future Growth Plans",
            "description": "<p></p><p>The latest update is out from Silicom ( <a data-ticker=\"SILC\" href=\"https://www.tipranks.com/stocks/silc\">(SILC)</a> ).</p>\n<p></p>\n<p></p><p>Silicom Ltd. announced its financial results for the third quarter of 2025, reporting revenues of $15.6 million, a slight increase from the previous year, but also a net loss of $2.8 million on a GAAP basis. Despite the losses, the company achieved significant strategic milestones, including eight Design Wins, and anticipates double-digit growth in 2026 driven by advancements in Post-Quantum Cryptography and Edge solutions. The company is optimistic about future growth, targeting 7 to 9 new Design Wins in 2026, leveraging its strong technology portfolio and customer relationships.</p>\n<p>The most recent analyst rating on <a data-ticker=\"SILC\" href=\"https://www.tipranks.com/stocks/silc\">(SILC)</a> stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Silicom stock, see the SILC <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/silc/forecast\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Stock Forecast page</a></span>.</p>\n<p><b><u>Spark’s Take on SILC Stock</u></b></p>\n<p>According to Spark, TipRanks’ <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/artificial-intelligence\">AI</a> Analyst, SILC is a Neutral.</p>\n<p>Silicom’s overall score reflects its strong balance sheet and cash flow management, which provide a buffer against current financial challenges. The earnings call optimism and design win momentum suggest potential for future growth, but current valuation metrics and technical indicators show caution.</p>\n<p>To see Spark’s full report on SILC stock, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/silc/ai-stock-analysis\" target=\"_blank\" ;=\"\" rel=\"nofollow\">click here</a></span>. </p>\n<p><b><u>More about Silicom</u></b></p>\n<p>Silicom Ltd. is a leading provider of high-performance networking and data infrastructure solutions, primarily targeting Cloud and Data Center environments. Their products are designed to enhance performance and efficiency, supporting technologies like NFV, SD-WAN, and Cyber Security. Silicom’s solutions are utilized by major Cloud players, service providers, telcos, and OEMs globally.</p>\n<p><b>Average Trading Volume:</b> 21,912</p>\n<p><b>Technical Sentiment Signal:</b> Hold</p>\n<p><b>Current Market Cap:</b> $105.9M</p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1928816210-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/silicom-reports-q3-2025-results-with-strategic-wins-and-future-growth-plans",
            "author": "TipRanks Auto-Generated Newsdesk",
            "pub_date": "2025-10-30 20:35:43",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2562597,
            "title": "BioCardia Advances Phase 3 CardiAMP HF II Trial",
            "description": "<p></p><p>BioCardia ( <a data-ticker=\"BCDA\" href=\"https://www.tipranks.com/stocks/bcda\">(BCDA)</a> ) has issued an update.</p>\n<p></p>\n<p></p><p>On October 30, 2025, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/bcda\" target=\"_blank\" ;=\"\" rel=\"nofollow\">BioCardia</a></span>, Inc. announced that the University of Wisconsin School of Medicine and Public Health enrolled its first patient in the ongoing Phase 3 CardiAMP HF II clinical trial. This trial aims to confirm the safety and efficacy of CardiAMP autologous cell therapy for ischemic heart failure patients with reduced ejection fraction. The study, which involves 250 patients, utilizes a composite primary outcome measure and incorporates advancements in cell population analysis and delivery systems. The enrollment at this prestigious cardiology center is expected to strengthen the trial and potentially broaden the availability of this therapy.</p>\n<p>The most recent analyst rating on <a data-ticker=\"BCDA\" href=\"https://www.tipranks.com/stocks/bcda\">(BCDA)</a> stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/bcda/forecast\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Stock Forecast page</a></span>.</p>\n<p><b><u>Spark’s Take on BCDA Stock</u></b></p>\n<p>According to Spark, TipRanks’ <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/artificial-intelligence\">AI</a> Analyst, BCDA is a Neutral.</p>\n<p>BioCardia’s overall stock score reflects significant financial challenges and a bearish technical outlook. While the earnings call provided some positive developments in clinical trials and regulatory progress, the financial instability and negative valuation metrics weigh heavily on the score.</p>\n<p>To see Spark’s full report on BCDA stock, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/bcda/ai-stock-analysis\" target=\"_blank\" ;=\"\" rel=\"nofollow\">click here</a></span>. </p>\n<p><b><u>More about BioCardia</u></b></p>\n<p>BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. The company focuses on biotherapeutic platforms such as CardiAMP autologous and CardiALLO allogeneic cell therapies, supported by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.</p>\n<p><b>Average Trading Volume:</b> 763,339</p>\n<p><b>Technical Sentiment Signal:</b> Strong Sell</p>\n<p><b>Current Market Cap:</b> $13.9M</p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1561815367-1-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/biocardia-advances-phase-3-cardiamp-hf-ii-trial-2",
            "author": "TipRanks Auto-Generated Newsdesk",
            "pub_date": "2025-10-30 20:30:35",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2562445,
            "title": "TDH Holdings Announces Results of 2025 Shareholder Meeting",
            "description": "<p></p><p>Tdh Holdings ( <a data-ticker=\"PETZ\" href=\"https://www.tipranks.com/stocks/petz\">(PETZ)</a> ) just unveiled an update.</p>\n<p></p>\n<p></p><p>TDH Holdings, Inc. recently held its 2025 annual shareholder meeting on October 29, 2025, where a quorum was present. During this meeting, shareholders approved three key proposals: the election of two Class B directors, the ratification of YCM CPA Inc. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and the approval of other business matters. These decisions are expected to impact the company’s governance and financial oversight positively.</p>\n<p><b><u>Spark’s Take on PETZ Stock</u></b></p>\n<p>According to Spark, TipRanks’ <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/artificial-intelligence\">AI</a> Analyst, PETZ is a Underperform.</p>\n<p>The overall score reflects significant financial struggles, particularly in profitability and cash flow. Technical analysis presents a neutral outlook, but valuation is heavily impacted by negative earnings. The company’s financial health is the primary concern, overshadowing any neutral technical trends.</p>\n<p>To see Spark’s full report on PETZ stock, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/petz/ai-stock-analysis\" target=\"_blank\" ;=\"\" rel=\"nofollow\">click here</a></span>. </p>\n<p><b><u>More about Tdh Holdings</u></b></p>\n<p><b>Average Trading Volume:</b> 113,388</p>\n<p><b>Technical Sentiment Signal:</b> Strong Sell</p>\n<p><b>Current Market Cap:</b> $10.94M</p>\n<p></p>\n<p></p><p>See more data about PETZ stock on <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/petz\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Consumer-Cylical-6-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/tdh-holdings-announces-results-of-2025-shareholder-meeting",
            "author": "TipRanks Auto-Generated Newsdesk",
            "pub_date": "2025-10-30 20:20:03",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2562375,
            "title": "Beijing Jingcheng Machinery Electric Co Ltd Updates Governance Structure",
            "description": "<p></p><p>An announcement from Beijing Jingcheng Machinery Electric Co Ltd Class H ( <a data-ticker=\"HK:0187\" href=\"https://www.tipranks.com/stocks/hk:0187\">(HK:0187)</a> ) is now available.</p>\n<p></p>\n<p></p><p>Beijing Jingcheng Machinery Electric Co Ltd has announced amendments to its corporate governance documents, including the Articles of Association and Rules of Procedure, while abolishing its supervisory committee. These changes are aimed at improving governance in line with updated laws and regulations, with the audit committee assuming the supervisory committee’s responsibilities, and adjustments made to the roles and obligations of shareholders and directors.</p>\n<p><b><u>More about Beijing Jingcheng Machinery Electric Co Ltd Class H</u></b></p>\n<p>Beijing Jingcheng Machinery Electric Co Ltd is a joint stock company incorporated in China, focusing on machinery and electric products. It operates within the manufacturing industry, with a market focus on enhancing corporate governance and aligning with updated regulatory standards.</p>\n<p><b>Average Trading Volume:</b> 8,101,709</p>\n<p><b>Technical Sentiment Signal:</b> Buy</p>\n<p><b>Current Market Cap:</b> HK$6.45B</p>\n<p></p>\n<p></p><p>Learn more about 0187 stock on <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/hk:0187\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Industrials-4-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/beijing-jingcheng-machinery-electric-co-ltd-updates-governance-structure",
            "author": "TipRanks HongKong Auto-Generated Newsdesk",
            "pub_date": "2025-10-30 20:14:33",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2562322,
            "title": "Kunlun Energy’s Associate CCNG in Talks for Equity Sale",
            "description": "<p></p><p>The latest announcement is out from KUNLUN ENERGY ( <a data-ticker=\"HK:0135\" href=\"https://www.tipranks.com/stocks/hk:0135\">(HK:0135)</a> ).</p>\n<p></p>\n<p></p><p>Kunlun Energy announced that China City Natural Gas Investment Group Co., Ltd. (CCNG), in which Kunlun Energy holds a 49% stake, is in negotiations with Shandong Shengli Co., Ltd. for the potential sale of equity interests in two subsidiaries. CCNG may sell a 51% stake in Nantong Oil &amp; Gas Co., Ltd. and a 40% stake in Qinghai China Oil Ganhe Industrial Park Gas Co., Ltd. to Shengli Share. The transactions, which involve share issuance and cash consideration, are not yet finalized and may not materialize.</p>\n<p>The most recent analyst rating on <a data-ticker=\"HK:0135\" href=\"https://www.tipranks.com/stocks/hk:0135\">(HK:0135)</a> stock is a Buy with a HK$8.00 price target. To see the full list of analyst forecasts on KUNLUN ENERGY stock, see the HK:0135 <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/hk:0135/forecast\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Stock Forecast page</a></span>.</p>\n<p><b><u>More about KUNLUN ENERGY</u></b></p>\n<p>Kunlun Energy Company Limited, incorporated in Bermuda, operates in the natural gas industry. The company is primarily involved in investment holding and the gas business, focusing on the purchase and sale of natural gas and gas pipeline construction.</p>\n<p><b>Average Trading Volume:</b> 14,458,189</p>\n<p><b>Technical Sentiment Signal:</b> Strong Buy</p>\n<p><b>Current Market Cap:</b> HK$62.86B</p>\n<p></p>\n<p></p><p>See more insights into 0135 stock on <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/hk:0135\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Energy-8-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/kunlun-energys-associate-ccng-in-talks-for-equity-sale",
            "author": "TipRanks HongKong Auto-Generated Newsdesk",
            "pub_date": "2025-10-30 20:10:35",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2562262,
            "title": "Rana Gruber ASA Secures Iron Ore Swap Contracts for 2026",
            "description": "<p></p><p>Rana Gruber AS ( <a data-ticker=\"DE:7XH\" href=\"https://www.tipranks.com/stocks/de:7xh\">(DE:7XH)</a> ) has shared an announcement.</p>\n<p></p>\n<p></p><p>Rana Gruber ASA has entered into swap contracts for iron ore shipments, agreeing to sell 45,000 metric tons per month in the second quarter of 2026 at an average price of $101.25 per metric ton. These contracts, which relate to physical shipments in the first quarter of 2026, indicate the company’s strategic positioning to manage price risks and stabilize revenue streams in the volatile iron ore market.</p>\n<p><b><u>More about Rana Gruber AS</u></b></p>\n<p>Rana Gruber is a Norwegian iron ore producer established in 1964, with operations based on more than 200 years of mining experience. The company’s products are based on natural mineral resources, which are processed and exported to customers worldwide. Key customers include steel producers and participants in the chemical industry. The company has about 370 employees and a production capacity of 1.8 million metric tons of iron ore concentrates.</p>\n<p><b>Average Trading Volume:</b> 79,349</p>\n<p><b>Current Market Cap:</b> NOK2.37B</p>\n<p></p>\n<p></p><p>See more insights into 7XH stock on <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/de:7xh\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2190929559-1-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/rana-gruber-asa-secures-iron-ore-swap-contracts-for-2026",
            "author": "TipRanks European Auto-Generated Newsdesk",
            "pub_date": "2025-10-30 20:04:39",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2562226,
            "title": "Westlake Corporation Reports Q3 2025 Financial Loss",
            "description": "<p></p><p>Westlake Corporation ( <a data-ticker=\"WLK\" href=\"https://www.tipranks.com/stocks/wlk\">(WLK)</a> ) has issued an update.</p>\n<p></p>\n<p></p><p><span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/wlk\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Westlake Corporation</a></span> reported its third quarter 2025 financial results, revealing a net loss of $782 million due to a significant non-cash impairment charge related to its North American chlorovinyls business. The company’s EBITDA, excluding identified items, decreased compared to both the previous quarter and the same quarter in 2024, primarily due to lower sales prices and volumes in its Performance and Essential Materials segment, as well as administrative and restructuring expenses in its Housing and Infrastructure Products segment.</p>\n<p>The most recent analyst rating on <a data-ticker=\"WLK\" href=\"https://www.tipranks.com/stocks/wlk\">(WLK)</a> stock is a Buy with a $93.00 price target. To see the full list of analyst forecasts on Westlake Corporation stock, see the WLK <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/wlk/forecast\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Stock Forecast page</a></span>.</p>\n<p><b><u>Spark’s Take on WLK Stock</u></b></p>\n<p>According to Spark, TipRanks’ <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/artificial-intelligence\">AI</a> Analyst, WLK is a Neutral.</p>\n<p>Westlake Corporation’s overall stock score reflects significant financial and operational challenges, with declining revenues and profitability pressures being the most impactful factors. Technical analysis suggests bearish momentum, and valuation metrics are unattractive due to a negative P/E ratio. While the earnings call provided some positive strategic insights, execution risks and segment-specific challenges remain.</p>\n<p>To see Spark’s full report on WLK stock, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/wlk/ai-stock-analysis\" target=\"_blank\" ;=\"\" rel=\"nofollow\">click here</a></span>. </p>\n<p><b><u>More about Westlake Corporation</u></b></p>\n<p>Westlake Corporation operates in the chemical industry, focusing on the production of essential materials and housing and infrastructure products. The company is known for its chlorovinyls and other performance materials, serving various industrial and manufacturing sectors.</p>\n<p><b>Average Trading Volume:</b> 1,163,017</p>\n<p><b>Technical Sentiment Signal:</b> Sell</p>\n<p><b>Current Market Cap:</b> $9.42B</p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1740531587-2-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/westlake-corporation-reports-q3-2025-financial-loss",
            "author": "TipRanks Auto-Generated Newsdesk",
            "pub_date": "2025-10-30 20:00:30",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2562144,
            "title": "NLS Pharmaceutics Expands CNS Pipeline with AEX-6xx Series",
            "description": "<p></p><p>NLS Pharmaceutics ( <a data-ticker=\"NLSP\" href=\"https://www.tipranks.com/stocks/nlsp\">(NLSP)</a> ) has shared an announcement.</p>\n<p></p>\n<p></p><p>On October 30, 2025, NLS Pharmaceutics announced the expansion of its DOXA platform with the AEX-6xx series, developed in collaboration with Aexon Labs. This new generation of small molecules targets arousal stability, cognition, and neuroprotection, with potential applications in conditions like Parkinson’s disease. The expansion strengthens NLS’s position in CNS innovation and aligns with the upcoming merger with Kadimastem, forming NewCelX. The company has secured significant funding, including a $25 million equity line of credit, to support future clinical programs and operations.</p>\n<p><b><u>More about NLS Pharmaceutics</u></b></p>\n<p>NLS Pharmaceutics is a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central nervous system and neurodegenerative disorders. Following its merger with Kadimastem Ltd., it will operate as NewCelX Ltd., a bi-continental biotech platform integrating Israeli innovation and listed on Nasdaq under the symbol ‘NCEL’.</p>\n<p><b>Average Trading Volume:</b> 696,972</p>\n<p><b>Technical Sentiment Signal:</b> Sell</p>\n<p><b>Current Market Cap:</b> $3.15M</p>\n<p></p>\n<p></p><p>Find detailed analytics on NLSP stock on <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/nlsp\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2127549605-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/nls-pharmaceutics-expands-cns-pipeline-with-aex-6xx-series",
            "author": "TipRanks Auto-Generated Newsdesk",
            "pub_date": "2025-10-30 19:55:19",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        }
    ]
}